Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. <i>J. Clin. Med.</i> 2019, <i>8</i>, 1066
The authors wish to make the following corrections to the previous publication [...]
Main Authors: | Domenico Russo, Rocco Tripepi, Fabio Malberti, Biagio Di Iorio, Bernadette Scognamiglio, Luca Di Lullo, Immacolata Gaia Paduano, Giovanni Luigi Tripepi, Vincenzo Antonio Panuccio |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/4/1224 |
Similar Items
-
Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report
by: Vincenzo Antonio Panuccio, et al.
Published: (2023-02-01) -
Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
by: Cozzolino M, et al.
Published: (2017-06-01) -
Paget’s Disease and Secondary Hyperparathyroidism: Is Healing Possible?
by: Vincenzo Antonio Panuccio, et al.
Published: (2020-05-01) -
Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
by: Eidman KE, et al.
Published: (2018-02-01) -
Editorial: Secondary hyperparathyroidism: an ongoing challenge for the nephrologist
by: Claudia Torino, et al.
Published: (2023-11-01)